期刊文献+

Cardeva对巴马小型猪环鸟甘酸和血压的影响

The Effects of Cardeva on Plasma cGMP and Blood Pressure in Chinese Bama Minipigs
下载PDF
导出
摘要 目的研究Cardeva对巴马小型猪的血浆及尿液内的环鸟苷酸(cyclic guanylic acid,cGMP)水平和血压的变化影响。方法将16头健康雌性巴马小型猪均分四组:高糖高脂饲料对照组(静注生理盐水,6 mL/头),高糖高脂饲料给药组(静注Cardeva,4 mg/kg);正常饲料对照组(静注生理盐水,6 mL/头)和正常饲料给药组(静注Cardeva,4 mg/kg)。收集给药前及给药后1、8、16、24、48、72 h的血样和尿样,测其cGMP水平;并测量静注前及静注后18、、16、24 h的血压变化。结果给药前高糖高脂饲料饲养的两组巴马猪均血压较高,且血浆和尿样内的cGMP水平低于正常饲料饲养的两组(均P<0.01)。给药组静注Cardeva后1 h血压降低,血浆和尿液中的cGMP水平均显著高于相应的对照组(P<0.05)。结论静注Cardeva可以迅速升高正常饮食和高糖高脂饮食的巴马小型猪血浆和尿液的cGMP水平,并使收缩压降低。 Objective To explore the effects of Cardeva on plasma and urine cGMP and blood pressure in Chinese Bama minipigs. Methods Sixteen female Chinese Bama miniature pigs were divided into four groups: HFSD (high - fat/high - sucrose diet , HFSD) + vehicle group(vehicle, 6mL, I.V. ), HFSD + Cardeva group ( Cardeva,4 mg/kg, I.V. ), CD ( control diet, CD) + vehicle group ( vehicle, 6mL, I.V. ), CD + Cardeva group ( Cardeva,4 mg/kg, I.V. ). Plasma and urine samples before and at 1, 8, 16, 24, 48, 72 h after drug or vehicle administration were collected. The levels of cGMP in plasma and urine were measured. Blood pressure was measured before and at 1, 8, 16, 24 h after infusion of vehicle or cardeva. Results The two groups of HFSD had low plasma and urine cGMP levels and high blood pressure before Cardeva administration. There were significant differences between cardeva and vehicle infusion in both plasma and urine cGMP at 1 h. Blood pressures of cardeva infusion HFSD minipigs was lower than that of HFSD group received vehicle at 1 h. Conclusions Cardeva could quickly improve plasma and urine cGMP level and lower systolic blood pressure after intravenous infusion in both CD and HFSD group of Bama minipigs.
出处 《南华大学学报(医学版)》 2008年第3期289-292,共4页 Journal of Nanhua University(Medical Edition)
关键词 Cardeva 脑钠肽 环乌苷酸 巴马小型猪 Cardeva Brain natriuretic peptide Cyclic guanylic acid Bama minipigs
  • 相关文献

参考文献7

  • 1Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B - type natriuretic peptide in the di- agnosis of congestive heart failure in an urgentcare setting[J]. J Am Coll Cardiol, 2001,37: 379 - 385.
  • 2Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B - natriuretic peptide assay in differentiating eongestive heart failure from lung disease in patients presenting with dyspnea[J]. J Am Coll Cardiol, 2002,39:202- 209.
  • 3Kawai K, Hata K, Takaoka H, et al. Plasmabrain natriuretic peptide as a novel therapeu- tic indicator in idiopathic dilated cardiomyopathy during beta - blocker therapy: a potential of hormoneguided treatment [J]. Am Heart J, 2001,141:925 - 932.
  • 4Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriurefic peptide and left ventricular remodeling in patients with congestive heart failure [J].J Am Coll Cardiol, 2001,37:1228 - 1233.
  • 5Brunner- La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects[J]. J Am Coll Cardiol, 2001, 37 : 1221 - 1227.
  • 6Aronson D, Burger AJ. Intravenous nesiritide (human Btype natriuretic peptide ) reduces plasma endothelin- 1 levels in patients with decompensated congestive heart failure [ J]. Am J Cardiol, 2002, 90:435-438.
  • 7Jonathan D, Sackner - Bernstein MD, Marcin Kowalski MD, et al. Short- term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials [ J]. JAMA, 2005, 293 ( 15 ) : 1900- 1905.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部